PharmacovigilanceOfficial
European Commission grants marketing authorisation for senaparib product Sepalna to SFL Pharmaceuticals Deutschland
🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026
Commission Decision (2026) 8204 of 12 November 2026 authorises Sepalna (senaparib), starting the company's post-authorisation obligations in the EU.
The European Commission has granted a new marketing authorisation for Sepalna (senaparib) to SFL Pharmaceuticals Deutschland GmbH. The authorisation was issued through Commission Decision (2026) 8204 on 12 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Official source: European Commission (Union Register) ↗
Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.
More Pharmacovigilance
All →
Commission grants marketing authorisation for Revolution Medicines' daraxonrasib product Rasonque
🇪🇺 European Commission (Union Register) · Mon 16 Nov 2026
Pleasanton drug discovery firm Cyion to pay $528,336 over alleged False Claims Act grant violations
🇺🇸 HHS OIG · Mon 16 Nov 2026
Real4Reg final symposium at Infarmed showcases real-world data studies and free training
🇵🇹 INFARMED · Mon 16 Nov 2026
Baltic paper-free leaflet project to continue after 2026 with Commission's backing
🇪🇪 Ravimiamet · Mon 16 Nov 2026
Medline details repair and replace programme for recalled beds, rails, mattresses and accessories
🇺🇸 FDA MedWatch · Fri 13 Nov 2026
PRAC publishes final EU-language translations of phenobarbital product information in targeted signal procedure
🇪🇺 EMA · PRAC · Fri 13 Nov 2026